Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?

References

• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North America Menopause Society. Maturitas 2014;79:349–54.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9.
   PubMed Web of Science ®Google Scholar
• Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013;19:155–62.
   PubMedGoogle Scholar
• Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014;33:1086–91.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson C, et al. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med 2011;8:1603–15.
   PubMed Web of Science ®Google Scholar
• Weber MA, Lim V, Oryszczyn J, et al. The effect of vaginal oestriol cream on subjective and objective symptoms of stress urinary incontinence and vaginal atrophy: an international multi-centre pilot study. Gynecol Obstet Invest 2017;82:15–21.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;8:CD001500.
   Google Scholar
• Nappi RE, Palacios S, Particco M, et al. Results of the European REVIVE (real women’s view of treatment options for menopausal vulvar/vaginal changes) survey. Maturitas 2015;81:106–83.
   Google Scholar
• Schiavi MC, Di Tucci C, Colagiovanni V, et al. A medical device containing purified bovine colostrum (monurelle biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: retrospective analysis of urinary symptoms, sexual function, and quality of life. Low Urin Tract Symptoms 2017. [Epub ahead of print]. DOI:10.1111/luts.12204
   PubMedGoogle Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–82.
   PubMed Web of Science ®Google Scholar
• Bondi C, Ferrero S, Scala C, et al. Pharmacokinetics, pharmaco-dynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opin Drug Metab Toxicol 2016;12:1233–46.
   PubMed Web of Science ®Google Scholar
• Abdelbary AM, El-Dessoukey AA, Massoud AM, et al. Combined vaginal pelvic floor electrical stimulation (PFS) and local vaginal estrogen for treatment of overactive bladder (OAB) in perimenopausal females. Randomized controlled trial (RCT)). Urology 2015;86:482–6.
   PubMed Web of Science ®Google Scholar
• Visco AG, Wei JT, McClure LA, et al. Effects of examination technique modifications on pelvic organ prolapse quantification (POP-Q) results. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:136–40.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Perniola GD, Di Donato V, et al. Severe pelvic organ prolapse treated by vaginal native tissue repair: long-term analysis of outcomes in 146 patients. Arch Gynecol Obstet 2017;295:917–22.
   PubMed Web of Science ®Google Scholar
• Coyne K, Schmier J, Hunt T, et al. Developing a specific HRQL instrument for overactive bladder. Value Health 2000;3:141.
   Google Scholar
• Bachman G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22:S1–S5.
   PubMed Web of Science ®Google Scholar
• Crisp CC, Felliner AN, Pauls RN, et al. Validation of the female sexual function index (FSFI) for web-based administration. Int Urogynecol J 2015;26:219–2215.
   PubMed Web of Science ®Google Scholar
• Derogatis L, Clayton A, Lewis-D'Agostino D, et al. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008;5:357–64.
   PubMed Web of Science ®Google Scholar
• Burholt V, Nash P. Short form 36 (SF-36) health survey questionnaire: normative data for Wales. J Public Health (Oxf) 2011;33:587–603.
   PubMed Web of Science ®Google Scholar
• Steinert T, Eisele F, Langle G, et al. PGI-I (patient’s global impression) as an outcome and quality indicator psychiatric in-patient treatment: results and concordance with doctor’s assessments. Psychiatr Prax 2010;37:343–9.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Ramsay IN. The psychosocial impact of urinary incontinence in women. Obstet Gynaecol 2011;13:143–8.
   Google Scholar
• Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 2009;12:279–85.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Particco M, Biglia N, et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: evidence from the European REVIVE survey. Maturitas 2016;91:74–80.
   PubMed Web of Science ®Google Scholar
• Minkin MJ, Maamari R, Reiter S, et al. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health 2013;5:133–9.
   PubMedGoogle Scholar
• Alvisi S, Baldassarre M, Martelli V, et al. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol 2017;33:946–50.
   PubMed Web of Science ®Google Scholar
• De Gregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 2014;90:82–93.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother 2015;16:2703–14.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol 2017;33:942–5.
   PubMed Web of Science ®Google Scholar